Companies /Healthcare

Codexis Inc

NASDAQ: CDXS Biotechnology
$1.01
▼ $0.04 (−3.81%) today
Markets closed · 3:39pm ET

CDXS at a Glance

Valuation
Market cap
$110.7M
Profitability
Revenue (TTM)
$88.3M
Profit margin
-21.8%
EPS (TTM)
$-0.18
Price
52-week range
$1 – $3
Street target
$6.14

Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: CDXS codexis.com

About Codexis

Codexis, Inc. provides enzymatic solutions for manufacturing complex therapeutics.

Its BioCatalysis business supplies high-performance engineered enzymes used to manufacture multiple commercially available small-molecule drugs. This business generates product revenue, which recently grew as customers approved and launched new, higher-margin products. The company also earns research and development revenue from collaborations.

Its main development focus is the proprietary ECO Synthesis Manufacturing Platform. This aqueous enzymatic process is intended as a scalable alternative to traditional solid-phase chemical synthesis of oligonucleotides. It is initially aimed at RNAi and siRNA therapeutics, with potential benefits including:
- Higher yields and purity
- Control of stereoisomers
- Reduced energy use and waste
- Lower capital requirements

Codexis is working with siRNA drug innovators, including through feasibility studies, and with contract development and manufacturing organizations (CDMOs). It plans to build an ECO GMP Manufacturing Center to supply siRNA material for preclinical and Phase 1/2 clinical trials. Updated

CDXS Coverage

1:20pm ET
Investing

Green Energy Avoids Tumble Off Fiscal Cliff

Any tax legislation worth the name carries with it a host of hangers on that represent special gifts to special interests. The American Taxpayer Relief Act of 2012 is no different. Here…

Paul Ausick

Frequently Asked Questions

What does Codexis do?

Codexis, Inc. provides enzymatic solutions for manufacturing complex therapeutics. Its BioCatalysis business supplies high-performance engineered enzymes used to manufacture multiple commercially available small-molecule drugs.

What is the CDXS stock price target?

The Wall Street consensus 12-month price target for CDXS is $6.14.